About the Event
Silence Therapeutics is developing a targeted treatment for the 132 million people at risk of heart disease thanks to high Lp(a) levels.
Join our webinar with Silence CEO, Craig Tooman, to hear how their mRNAi Gold Platform has created a therapy that has the potential to exceed the sales of blockbuster drugs like Lipitor, Crestor, and Zocor.